Treatment Options for Mucormycosis

摘要: Mucormycosis, which occurs primarily in immunosuppressed patients and with diabetes mellitus, remains one of the most difficult fungal infections to treat. In part, this is due poor immune response those who have hematological malignancies or received a hematopoietic cell solid organ transplant, but also very important paucity available non-toxic effective antifungal agents. Correction underlying risk factors helpful, possible mostly diabetes. Surgical debridement all necrotic tissue crucially decreasing mortality. Lipid formulations amphotericin B are treatment choice. Posaconazole oral suspension has been used successfully salvage trials allows long-term therapy that was not previously. The new delayed-release tablet achieves higher serum concentrations should prove be more efficacious than step-down after initial treatment. Isavuconazole newly approved azole appears against mucormycosis studies. Similar posaconazole, capsule use as Both these azoles now intravenous perhaps may primary for mucormycosis, until clinical shown indeed, they efficacious, agents considered appropriate mucormycosis.